AC:PSEAyala Corp. Analysis
Data as of 2026-03-14 - not real-time
$196.65
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Accenture (AC) is trading at $196.65, well below its 20‑day ($208.18), 50‑day ($242.28) and 200‑day ($259.53) simple moving averages, signaling a bearish technical backdrop. However, the RSI of 32.6 indicates oversold conditions and the MACD histogram turning positive (+0.81) suggests a potential short‑term bounce. The stock’s price is near the identified support level of $188.73 and far from the resistance at $229.11, offering a modest upside cushion. Fundamentally, AC trades at a forward PE of 13.2 versus an industry average of 33.7, delivering a value premium alongside a modest 6% revenue growth and a robust 25% ROE. The dividend yield of 3.32% with a 50% payout ratio is backed by $11.12 B of free cash flow and a low debt‑to‑equity of 25.7%, indicating solid sustainability. Analysts (27) rate the stock as a “buy” with a mean target of $280, implying roughly 42% upside relative to the current price and a DCF‑derived fair value of $317.57.
The high 30‑day volatility (≈53%) and a beta under 1 point to heightened price swings but limited systematic risk, while decreasing volume hints at waning short‑term participation. Despite the bearish trend, the combination of strong cash generation, attractive valuation multiples, and a generous dividend makes AC a compelling candidate for investors seeking a blend of growth and income, especially given its strategic AI and cloud partnerships that could fuel long‑term earnings expansion.
The high 30‑day volatility (≈53%) and a beta under 1 point to heightened price swings but limited systematic risk, while decreasing volume hints at waning short‑term participation. Despite the bearish trend, the combination of strong cash generation, attractive valuation multiples, and a generous dividend makes AC a compelling candidate for investors seeking a blend of growth and income, especially given its strategic AI and cloud partnerships that could fuel long‑term earnings expansion.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold RSI and bullish MACD histogram
- Proximity to strong support level
- Attractive dividend yield with solid cash flow
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap to DCF fair value
- Consistent earnings growth and high ROE
- Analyst consensus and upward target prices
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strategic AI and cloud partnerships driving future growth
- Sustainable dividend supported by free cash flow
- Low leverage and strong balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth6.00%
Profit Margin10.76%
P/E Ratio16.3
ROE25.02%
ROA11.13%
Debt/Equity25.69
P/B Ratio3.9
Op. Cash Flow$12.1B
Free Cash Flow$11.1B
Industry P/E33.7
Technical Analysis
TrendBearish
RSI32.6
Support$188.73
Resistance$229.11
MA 20$208.18
MA 50$242.28
MA 200$259.53
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair Value$317.57
Target Price$280.22
Upside/Downside42.50%
GradeUndervalued
TypeBlend
Dividend Yield3.32%
Risk Assessment
Beta0.85
Volatility52.73%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.